Peptides & the FDA review: your questions, answered

Peppies was founded by an entrepreneur with a track record of turning confusing consumer problems into organized public action. We don't sell peptides, and we're transparent about the incentive: we'd benefit only from a legal, regulated market - the same outcome that makes people safer - not from today's grey market. Full disclosure is here.

No. The vote is only a recommendation. Real access would change only if the FDA later opens a formal rulemaking - which is also the stage with a public comment window where an ordinary person's input carries legal weight. How the process works →

A licensed compounding pharmacy is inspected, dispenses against a prescription, and must meet identity, potency and sterility standards. An anonymous online seller does none of that. Telling them apart - and reporting the illegal ones - is covered step by step in Safety & the Grey Market.

Not exactly. The review is about whether pharmacies may legally compound these substances - building a legal, regulated pathway, not adding a new prohibition. Today most already have no cleared legal channel. Follow the status on the tracker.

The FDA-evaluated use listed for TB-500 is wound healing.¹

Not exactly. TB-500 is based on a fragment of the natural 43-amino-acid protein thymosin beta-4, and commercial 'TB-500' labeling is inconsistent - some products use the short actin-binding fragment, others the full protein.^{2 3}

TB-500 is not an FDA-approved drug and has no cleared compounding pathway. It was in Category 2 of the interim 503A list, then removed in April 2026 and referred to the July 2026 advisory committee. Removal did not place it on the approved list.^{1 4 5}

The FDA-evaluated uses listed for Semax are cerebral ischemia, migraine, and trigeminal neuralgia.⁶

No. Approval by another country's regulator does not confer FDA approval or U.S. legal status. The FDA evaluates the evidence independently.⁷

Semax is not FDA-approved and has no cleared compounding pathway in the U.S. It was in Category 2 of the interim 503A list, then removed in April 2026 and referred to the July 2026 advisory committee. Its approval in Russia does not make it approved here.^{6 8 9}